IL-10 in myeloma cells
- PMID: 12148907
- DOI: 10.1080/10428190290021579
IL-10 in myeloma cells
Abstract
In addition to interleukin (IL)-6, IL-10 is considered as one of the most important cytokines regulating the proliferation and cellular characteristics of myeloma cells. It is still unclear from the clinical data how serum IL-10 levels of various stages of myeloma, are related to clinical manifestations of this disease. Several studies have reported that IL-10 affects myeloma cells by stimulating secondary signals for cell proliferation through oncostatin M (OSM) and IL-11. In experiments using human myeloma cell lines established at our laboratory, IL-10 seemed to be expressed in half of myelomas simultaneously with OSM, and to be correlated with c-maf, a transcription factor, which has been known to be overexpressed in myelomas with t(14;16)(q32;q23). In addition, IL-10 abolishes all trans retinoic acid (ATRA)-induced growth inhibition of myeloma cells. The expression and production of IL-10 in myeloma patients may be important for sub-categorization and the establishment of a case-oriented therapy.
Similar articles
-
Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells.Br J Haematol. 2002 Mar;116(4):787-95. doi: 10.1046/j.0007-1048.2002.03336.x. Br J Haematol. 2002. PMID: 11886382
-
Interleukin-10 and Gp130 cytokines in human multiple myeloma.Leuk Lymphoma. 1999 Jun;34(1-2):63-70. doi: 10.3109/10428199909083381. Leuk Lymphoma. 1999. PMID: 10350333 Review.
-
Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.Eur Cytokine Netw. 2000 Sep;11(3):443-51. Eur Cytokine Netw. 2000. PMID: 11022130
-
Expression and production of interleukin 10 in human myeloma cell lines.Br J Haematol. 2000 Dec;111(3):835-42. Br J Haematol. 2000. PMID: 11122145
-
Effects of all-trans retinoic acid (ATRA) on human myeloma cells.Leuk Lymphoma. 2003 Oct;44(10):1651-6. doi: 10.1080/1042819031000099652. Leuk Lymphoma. 2003. PMID: 14692515 Review.
Cited by
-
Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia.Front Immunol. 2021 Oct 25;12:738915. doi: 10.3389/fimmu.2021.738915. eCollection 2021. Front Immunol. 2021. PMID: 34759921 Free PMC article. Review.
-
Plasma cells in immunopathology: concepts and therapeutic strategies.Semin Immunopathol. 2014 May;36(3):277-88. doi: 10.1007/s00281-014-0426-8. Epub 2014 Apr 17. Semin Immunopathol. 2014. PMID: 24740168 Review.
-
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):207-21. doi: 10.1007/s00005-008-0022-5. Epub 2008 May 30. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18512025 Free PMC article.
-
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.Cytokine. 2014 Oct;69(2):294-7. doi: 10.1016/j.cyto.2014.05.017. Epub 2014 Jul 17. Cytokine. 2014. PMID: 25043675 Free PMC article.
-
Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells.Oncotarget. 2017 Oct 7;8(54):92841-92854. doi: 10.18632/oncotarget.21611. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190960 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials